Zittermann A, Zelzer S, Herrmann M, Gummert J F, Kleber M, Trummer C, Theiler-Schwetz V, Keppel M H, Maerz W, Pilz S
Clinic for Thoracic and Cardiovascular Surgery, Herz, und Diabeteszentrum NRW, Ruhr-University Bochum, Bad Oeynhausen, 32545, Germany.
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz 8036, Austria.
J Steroid Biochem Mol Biol. 2024 Jul;241:106528. doi: 10.1016/j.jsbmb.2024.106528. Epub 2024 Apr 26.
Circulating calcitriol may contribute to the risk of cardiovascular disease (CVD), but its regulation in patients with CVD is poorly characterized. We therefore aimed to assess determinants of circulating calcitriol in these patients. We analyzed 2183 independent samples from a large cohort of patients scheduled for coronary angiography and 1727 independent samples from different other cohorts from patients with a wide range of CVDs, including heart transplant candidates, to quantify the association of different parameters with circulating calcitriol. We performed univariable and multivariable linear regression analyses using the mathematical function that fitted best with circulating calcitriol. In the multivariable analysis of the large single cohort, nine parameters remained significant, explaining 30.0 % (32.4 % after exclusion of 22 potential outliers) of the variation in circulating calcitriol (r=0.548). Log-transformed 25-hydroxyvitamin D [25(OH)D] and log-transformed glomerular filtration rate were the strongest predictors, explaining 17.6 % and 6.6 %, respectively, of the variation in calcitriol. In the analysis of the combined other cohorts, including heart transplant candidates, the multivariable model explained a total of 42.6 % (46.1 % after exclusion of 21 potential outliers) of the variation in calcitriol (r=0.653) with log-transformed fibroblast growth factor-23 and log-transformed 25(OH)D explaining 29.0 % and 6.2 %, respectively. Circulating 25(OH)D was positively and FGF-23 inversely associated with circulating calcitriol. Although significant, PTH was only a weak predictor of calcitriol in both analyses (<2.5 %). In patients with CVD, FGF-23 and 25(OH)D are important independent determinants of circulating calcitriol. The relative importance of these two parameters may vary according to CVD severity. Future studies should focus on the clinical importance of regulating circulating calcitriol by different parameters.
循环中的骨化三醇可能会增加心血管疾病(CVD)的风险,但其在CVD患者中的调节机制尚不清楚。因此,我们旨在评估这些患者循环骨化三醇的决定因素。我们分析了来自一大群计划进行冠状动脉造影的患者的2183个独立样本,以及来自不同其他队列的1727个独立样本,这些队列中的患者患有各种心血管疾病,包括心脏移植候选者,以量化不同参数与循环骨化三醇之间的关联。我们使用与循环骨化三醇拟合最佳的数学函数进行单变量和多变量线性回归分析。在对大型单一队列的多变量分析中,九个参数仍然显著,解释了循环骨化三醇变异的30.0%(排除22个潜在异常值后为32.4%)(r=0.548)。对数转换后的25-羟基维生素D [25(OH)D]和对数转换后的肾小球滤过率是最强的预测因子,分别解释了骨化三醇变异的17.6%和6.6%。在对包括心脏移植候选者在内的其他队列组合的分析中,多变量模型总共解释了骨化三醇变异的42.6%(排除21个潜在异常值后为46.1%)(r=0.653),对数转换后的成纤维细胞生长因子-23和对数转换后的25(OH)D分别解释了29.0%和6.2%。循环中的25(OH)D与循环骨化三醇呈正相关,而FGF-23与循环骨化三醇呈负相关。尽管具有显著性,但在两项分析中,甲状旁腺激素(PTH)只是骨化三醇的一个弱预测因子(<2.5%)。在CVD患者中,FGF-23和25(OH)D是循环骨化三醇的重要独立决定因素。这两个参数的相对重要性可能因CVD严重程度而异。未来的研究应关注通过不同参数调节循环骨化三醇的临床重要性。